Acetazolamide (app) is a carbonic anhydrase inhibitor that reduces cerebrospinal fluid production and intracranial pressure, potentially modulating neurogenic inflammation associated with cluster headaches. By decreasing metabolic activity and altering cerebral blood flow, it may help prevent or reduce the frequency and intensity of cluster headache episodes through its neurological and vascular regulatory effects.